GlassScriptPhysician profile
Phillip W Moye
NPI 1184761868
$12,441.76
in general payments reported to CMS, 2019-2025
63 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 97% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $1,165 · 2021: $2,032 · 2022: $2,082 · 2023: $2,434 · 2024: $2,236 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,849.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,354.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,181.07 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $932.89 | 2020-2025 | |
| Pfizer INC. | $894.16 | 2019-2025 | |
| Amgen INC. | $691.48 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $609.25 | 2020-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $467.12 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $450.18 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $377.73 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.03 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $331.38 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $296.91 | 2019-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $296.86 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $292.59 | 2020-2025 | Rexulti |
| Lilly USA, LLC | $222.27 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $202.75 | 2020-2025 | Nexletol, Nexlizet |
| Takeda Pharmaceuticals U.S.A., INC. | $200.08 | 2020-2023 | Trintellix |
| Aimmune Therapeutics, INC. | $191.62 | 2024-2025 | Zenpep |
| Scilex Pharmaceuticals INC. | $185.09 | 2020-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $180.39 | 2019-2024 | |
| Lundbeck LLC | $177.20 | 2020-2025 | Rexulti |
| Amarin Pharma, INC. | $173.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $145.07 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.53 | 2022 | |
| Sumitomo Pharma America, INC. | $144.34 | 2023-2025 | Gemtesa |
| Ardelyx, INC. | $139.04 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $134.67 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $101.66 | 2020-2022 | |
| Abbott Laboratories | $95.95 | 2024-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $94.44 | 2024-2025 | Voquezna |
| Upsher-Smith Laboratories LLC | $89.87 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $82.79 | 2020-2023 | Xarelto |
| Daiichi Sankyo INC. | $79.85 | 2022-2024 | Injectafer |
| Arbor Pharmaceuticals, INC. | $79.63 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $72.16 | 2022-2023 | Linzess |
| Azurity Pharmaceuticals, INC. | $68.06 | 2023-2024 | Adthyza, Horizant, Edarbi |
| Biohaven Pharmaceuticals, INC. | $67.87 | 2021 | |
| Ironshore Pharmaceuticals INC. | $65.95 | 2019-2022 | |
| Eisai INC. | $65.23 | 2020-2021 | |
| Corcept Therapeutics | $60.09 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $59.77 | 2025 | Fanapt, Hetlioz |
| Tolmar, INC. | $54.59 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $53.31 | 2019-2023 | Seglentis, Livalo |
| Exact Sciences Corporation | $52.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $48.30 | 2021-2022 | |
| Seqirus USA INC | $46.28 | 2025 | Fluad, Flucelvax |
| Axsome Therapeutics, INC. | $41.36 | 2023-2025 | Auvelity, Symbravo |
| Vivus LLC | $31.76 | 2022-2023 | Qsymia |
| Idorsia Pharmaceuticals US INC | $27.30 | 2022-2023 | Quviviq |
| Sanofi Pasteur INC. | $25.56 | 2020-2023 | |
| Medtronic, INC. | $21.62 | 2024 | Intellis Adaptivestim |
| Philips North America LLC | $17.70 | 2021 | |
| Allergan, INC. | $17.56 | 2019 | |
| Scynexis, INC. | $17.52 | 2022 | |
| Dexcom, INC. | $15.37 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $14.66 | 2021 | |
| Nabriva Therapeutics, Plc | $14.38 | 2021 | |
| Globus Medical, INC. | $14.36 | 2025 | Senza |
| Almatica Pharma LLC | $14.06 | 2025 | Teriparatide, Loreev Xr |
| Hikma Pharmaceuticals USA | $13.62 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.62 | 2021 | |
| Radius Health, INC. | $11.13 | 2021 | |
| Corium, LLC | $9.54 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Moye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.